Patents by Inventor Darius Ghaderi
Darius Ghaderi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240009306Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. In some embodiments, the present invention provides an antibody having a heavy chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 63 and having a light chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 64.Type: ApplicationFiled: November 7, 2022Publication date: January 11, 2024Applicant: Seagen Inc.Inventors: Ana Paula Galvao da Silva, Julie DeSander, Jeffrey Behrens, Darius Ghaderi, Mai Zhang, Kristan Meetze
-
Publication number: 20240002422Abstract: The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.Type: ApplicationFiled: February 28, 2023Publication date: January 4, 2024Applicant: Seagen Inc.Inventors: Ana Paula Galvao da Silva, Mai Zhang, Darius Ghaderi, Julie DeSander, Jeffrey Behrens, Jillian M. Prendergast
-
Publication number: 20220057402Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.Type: ApplicationFiled: May 26, 2021Publication date: February 24, 2022Applicant: Seagen Inc.Inventors: Ana Paula Galvao da Silva, Darius Ghaderi, Mai Zhang, Kristan Meetze, Julie DeSander, Jeffrey Behrens, David A. Eavarone, Jillian M. Prendergast
-
Publication number: 20210017213Abstract: The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.Type: ApplicationFiled: April 16, 2020Publication date: January 21, 2021Applicant: Seattle Genetics, Inc.Inventors: Ana Paula Galvao da Silva, Mai Zhang, Darius Ghaderi, Julie DeSander, Jeffrey Behrens, Jillian M. Prendergast
-
Publication number: 20210011021Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.Type: ApplicationFiled: February 14, 2020Publication date: January 14, 2021Applicant: Seattle Genetics, Inc.Inventors: Ana Paula Galvao da Silva, Darius Ghaderi, Mai Zhang, Kristan Meetze, Julie DeSander, Jeffrey Behrens, David A. Eavarone, Jillian M. Prendergast
-
Publication number: 20200276306Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include mono clonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. In some embodiments, the present invention provides an antibody having a heavy chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 63 and having a light chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 64.Type: ApplicationFiled: January 14, 2020Publication date: September 3, 2020Applicant: Seattle Genetics, Inc.Inventors: Ana Paula Galvao da Silva, Julie DeSander, Jeffrey Behrens, Darius Ghaderi, Mai Zhang, Kristan Meetze
-
Publication number: 20180280504Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them.Type: ApplicationFiled: October 9, 2015Publication date: October 4, 2018Inventors: Ana Paula Galvao da Silva, Julie DeSander, Jeffrey Behrens, Darius Ghaderi, Mai Zhang, Kristan Meetze
-
Publication number: 20170305950Abstract: The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.Type: ApplicationFiled: October 9, 2015Publication date: October 26, 2017Inventors: Ana Paula Galvao da Silva, Mai Zhang, Darius Ghaderi, Julie DeSander, Jeffrey Behrens, Jillian M. Prendergast
-
Publication number: 20170306046Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.Type: ApplicationFiled: November 12, 2015Publication date: October 26, 2017Inventors: Ana Paula Galvao daSilva, Darius Ghaderi, Mai Zhang, Kristan Meetze, Julie DeSander, Jeffrey Behrens, David A. Eavarone, Jillian M. Prendergast, Alexey Alexandrovich Lugovskoy
-
Publication number: 20160311922Abstract: The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.Type: ApplicationFiled: July 11, 2016Publication date: October 27, 2016Inventors: Darius Ghaderi, Ana Paula Galvao da Silva
-
Publication number: 20160264684Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.Type: ApplicationFiled: October 10, 2014Publication date: September 15, 2016Applicant: SIAMAB THERAPEUTICS, INC.Inventors: Ana Paula Galvao da Silva, Mai Zhang, Darius Ghaderi, Intan Purnajo, Julie DeSander, Jeffrey Behrens
-
Patent number: 9416194Abstract: The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.Type: GrantFiled: January 21, 2016Date of Patent: August 16, 2016Assignee: Siamab Therapeutics, Inc.Inventors: Darius Ghaderi, Ana Paula Galvao da Silva
-
Publication number: 20160137743Abstract: The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.Type: ApplicationFiled: January 21, 2016Publication date: May 19, 2016Inventors: DARIUS GHADERI, ANA PAULA GALVAO DA SILVA
-
Publication number: 20160106799Abstract: Embodiments of the present invention provide compositions and methods for the modulation of sialic acid levels. In some embodiments, compositions disclosed herein comprise nutraceuticals as functional agents.Type: ApplicationFiled: May 29, 2014Publication date: April 21, 2016Applicant: SIAMAB THERAPEUTICS, INC.Inventors: Mai Zhang, Darius Ghaderi, Jeffrey Behrens, Julie DeSander, Ajit Varki
-
Patent number: 9273142Abstract: The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.Type: GrantFiled: October 10, 2013Date of Patent: March 1, 2016Assignee: SIAMAB THERAPEUTICS, INC.Inventors: Darius Ghaderi, Ana Paula Galvao da Silva
-
Publication number: 20140178365Abstract: The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.Type: ApplicationFiled: October 10, 2013Publication date: June 26, 2014Applicant: SIALIX INCInventors: Darius Ghaderi, Ana Paula Galvao da Silva, Jeffrey Behrens, Julie Hermann, Nancy Hurtado-Ziola
-
Publication number: 20120045816Abstract: Provided herein are glycosylated polypeptide compositions with substantially reduced Neu5Gc content. The glycosylated polypeptides compositions with substantially reduced Neu5Gc content can be obtained from cell sources cultured with Neu5Gc competitor or from non-human animal sources fed a diet supplemented with Neu5Gc competitor. Also provided herein are methods of treating a human subject with said compositions.Type: ApplicationFiled: July 14, 2011Publication date: February 23, 2012Inventors: Darius Ghaderi, Ajit Varki